Inovio Pharmaceuticals Investors Alerted to Lawsuit Deadline
A law firm is reminding investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) of an April 7, 2026, deadline to lead a securities fraud lawsuit. The suit covers purchasers of the company's securities between October 2023 and December 2025. The case centers on allegations of misleading statements made by the biotechnology company.
- The lawsuit alleges Inovio failed to disclose manufacturing deficiencies with its CELLECTRA delivery device. This device is designed to deliver the company's DNA medicines. - At the center of the allegations is INO-3107, a product candidate for treating Recurrent Respiratory Papillomatosis (RRP), a rare HPV-related disease. The lawsuit claims Inovio overstated the product's regulatory and commercial prospects. - On August 8, 2024, the company announced a significant delay in submitting its Biologics License Application (BLA) for INO-3107, pushing the timeline from the second half of 2024 to mid-2025 due to a "manufacturing issue." Following this news, Inovio's stock price fell 3.1% to close at $8.44 per share on August 9, 2024. - The company's stock dropped again on December 29, 2025, after it was disclosed that the U.S. Food and Drug Administration (FDA) had accepted the BLA for INO-3107 under a standard review timeline, not the accelerated review that the company had previously suggested was possible. - Following the news of a standard FDA review, Inovio's stock price fell 24.45% to close at $1.73 per share on December 29, 2025. - Multiple law firms, including Glancy Prongay & Murray LLP and The Rosen Law Firm, are representing investors in the class action lawsuit. The case was filed in the United States District Court for the Eastern District of Pennsylvania.
